For decades, RAS mutations in pancreatic cancer have been called “undruggable.” Over 90% of pancreatic ductal adenocarcinoma (PDAC) tumors carry activating RAS mutations — yet until now, no drug has been able to effectively target this pathway in pancreatic cancer patients.

That changed with daraxonrasib (RMC-6236), a first-in-class oral pan-RAS(ON) inhibitor from Revolution Medicines. Published in the New England Journal of Medicine (2026), Phase 1-2 trial data shows dramatic improvements over standard chemotherapy in heavily pre-treated patients — with a safety profile that supports Phase 3 development.

Important: This article is for informational purposes only and does not constitute medical advice. Always consult with your treating oncologist before making any treatment decisions.

---

Why This Matters: The RAS Problem in Pancreatic Cancer

Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of approximately 13%. The vast majority of cases (>90%) are driven by mutations in the RAS family of oncogenes — most commonly KRAS.

Historically, RAS proteins have been considered “undruggable” because:

• They are small, smooth-surfaced proteins with no obvious drug-binding pockets
• They cycle rapidly between active (GTP-bound) and inactive (GDP-bound) states
• Previous drug开发 efforts focused on the inactive state, which is transient and hard to target

Daraxonrasib takes a different approach — it targets the active, GTP-bound state of RAS proteins (KRAS, HRAS, NRAS), covering a broad spectrum of RAS mutations. This is the state where RAS is actively driving cancer growth.

---

The Trial: Key Results

The Phase 1-2 trial enrolled 168 heavily pre-treated patients with RAS-mutated metastatic PDAC who had progressed on prior therapies. The 300 mg dose cohort produced the most compelling data:

Metric	RAS G12 Mutant (n=26)	All RAS Mutants (n=38)
Objective Response Rate (ORR)	35%	29%
Median Duration of Response	8.2 months	8.2 months
Median Progression-Free Survival	8.5 months	8.1 months
Median Overall Survival	13.1 months	15.6 months
Disease Control Rate (G12)	92%	—

How This Compares to Standard Chemotherapy

For previously treated metastatic PDAC, current chemotherapy typically achieves:

Metric	Standard Chemotherapy	Daraxonrasib	Improvement
ORR	<10%	29–35%	3–4x
Median PFS	2–3 months	8.1–8.5 months	2–3x
Median OS	5–7 months	13.1–15.6 months	~2x

The disease control rate of 92% in the G12 subgroup is particularly striking — meaning nearly all patients experienced tumor shrinkage or stable disease.

---

Safety Profile

The safety data is manageable and supports further development:

• Any-grade treatment-related adverse events (TRAEs): 96% of patients
• Grade ≥3 TRAEs: 30% of patients
• Grade 5 (fatal) events: None observed
• No patients discontinued treatment due to TRAEs

Most common side effects:

• Rash (88%) — mostly low-grade, managed with topical steroids
• Diarrhea (46%)
• Nausea (42%)

Dose-limiting toxicities: Primarily rash and mucositis, managed with dose adjustments and supportive care. The 300 mg dose was selected as the recommended Phase 2 dose based on favorable safety/efficacy balance.

---

Why Daraxonrasib Is Different

Several features make this drug stand out from previous RAS-targeting attempts:

1. Pan-RAS Coverage

Unlike drugs that target only specific KRAS mutations (e.g., sotorasib for G12C), daraxonrasib covers the full spectrum of RAS mutations — G12D, G12V, G12A, G12R, G13D, Q61, and others. This is critical because pancreatic cancer has diverse RAS mutation subtypes.

2. Active-State Targeting

By targeting the GTP-bound (active) state, daraxonrasib achieves >90% continuous inhibition of the RAS-MAPK pathway. Previous attempts targeting the inactive state couldn’t achieve sustained pathway suppression.

3. Tumor Preferential Accumulation

The drug achieves higher concentrations in tumor tissue than in normal tissue, contributing to its favorable therapeutic window.

4. Oral Administration

Daraxonrasib is taken orally, avoiding the complexity and inconvenience of intravenous therapies.

---

What This Means for International Patients

1. A New Treatment Option for a Critical Gap

Daraxonrasib addresses one of the biggest unmet needs in pancreatic cancer: effective later-line treatment. Currently, patients who progress on first-line chemotherapy (FOLFIRINOX or gemcitabine-based regimens) have very limited options with poor outcomes.

2. Phase 3 Trial Underway

The global Phase 3 RASolute 302 trial (NCT06625320) is comparing daraxonrasib vs. standard chemotherapy as second-line treatment for metastatic PDAC. This trial is actively recruiting and includes international sites.

3. Molecular Testing Is Essential

To be eligible for daraxonrasib or similar RAS-targeting therapies, patients need:

• RAS mutation testing — determines which specific mutation is present
• Comprehensive genomic profiling — may reveal additional actionable mutations
• Tissue or liquid biopsy — both can provide RAS mutation data

4. Access Pathways

Pathway	Details
Clinical trial	RASolute 302 (Phase 3) — actively recruiting globally
Compassionate use	May be available through Revolution Medicines expanded access programs
China trials	Monitor Chinese clinical trial registries for domestic RAS inhibitor studies

---

The Bigger Picture: RAS Inhibitors as Backbone Therapy

Daraxonrasib’s results open the door to combination strategies that could transform pancreatic cancer treatment:

1. RAS inhibitor + chemotherapy — Rapid tumor shrinkage from the inhibitor could sensitize tumors to chemotherapy
2. RAS inhibitor + immunotherapy — Pathway inhibition may remodel the tumor microenvironment, making it more receptive to immune checkpoint inhibitors
3. RAS inhibitor + vaccine — Reducing tumor burden first, then using a vaccine to establish immune surveillance against residual disease

This “RAS inhibitor first, then combination” approach is being actively explored and may represent the future of pancreatic cancer treatment.

---

The Bottom Line

Daraxonrasib represents a genuine breakthrough in pancreatic cancer treatment:

• First-in-class pan-RAS(ON) inhibitor with significant clinical activity in PDAC
• 3–4x higher response rate than chemotherapy in later-line patients
• 2–3x longer progression-free survival compared to standard care
• Manageable safety profile with no fatal treatment-related events
• Phase 3 trial underway — results could change the standard of care

For the >90% of pancreatic cancer patients with RAS mutations, this is the first time a targeted therapy has shown this level of efficacy. The science is moving from “undruggable” to “treatable” — and daraxonrasib is leading that transition.

---

This article is based on Phase 1-2 clinical trial data published in the New England Journal of Medicine (2026;394:1790-1802). The Phase 3 RASolute 302 trial (NCT06625320) is ongoing. For the latest trial information, contact our clinical trials team. This article does not constitute medical advice.